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Abstract Peroxisomes are dynamic organelles that play an
essential role in a variety of metabolic pathways.
Peroxisomal dysfunction can lead to various biochemical ab-
normalities and result in abnormal metabolite levels, such as
increased very long-chain fatty acid or reduced plasmalogen
levels. The metabolite abnormalities in peroxisomal disorders
are used in the diagnostics of these disorders. In this paper we
discuss in detail the different diagnostic tests available for
peroxisomal disorders and focus specifically on the important
role of biochemical and functional studies in cultured skin
fibroblasts in reaching the right diagnosis. Several examples
are shown to underline the power of such studies.
Peroxisomal disorders
Peroxisomal disorders form a group of inherited disorders
caused by mutations in genes encoding peroxisomal proteins,
which lead to one or more impaired peroxisomal functions or
cause the absence of functional peroxisomes altogether.
Peroxisomes are dynamic organelles that play an essential role
in a variety of cellular catabolic and anabolic metabolic path-
ways, including fatty acid alpha- and beta-oxidation, and
plasmalogen and bile acid biosynthesis (Wanders and
Waterham 2006a). A defect of one or more functions of the
peroxisome leads to abnormal metabolite levels, which is used
in the screening for peroxisomal disorders (Wanders and
Waterham 2006a, b; Van Veldhoven 2010). Peroxisomal dis-
orders can be divided in two main subgroups: 1) the peroxi-
some biogenesis disorders (Steinberg et al 2006; Waterham
and Ebberink 2012) and 2) the single enzyme defects
(Wanders and Waterham 2006b; Van Veldhoven 2010). Both
the clinical and genetic spectrum of the peroxisomal disorders
is still expanding. The peroxisome biogenesis disorders in-
clude not only the Zellweger spectrum disorders (ZSDs, with
an estimated incidence of 1 in 50,000 newborns in the United
States) and Rhizomelic chondrodysplasia punctata (RCDP)
type 1 (OMIM 215100), but also the recently identified
RCDP type 5 (Baroy et al 2015) and a novel subclass of
peroxisomal fission disorders (i.e. PEX11β (OMIM 614920)
(Ebberink et al 2012; Thoms and Gartner 2012), DLP/DRP1
(OMIM 614388) (Waterham et al 2007) and MFF
(Shamseldin et al 2012) deficiency). The group of the single
enzyme defects has expanded in the last 2 years with two
disorders, i.e. RCDP type 4 (FAR1 deficiency, OMIM
616154) (Buchert et al 2014) and ABCD3 deficiency
(OMIM 616278) (Ferdinandusse et al 2015). The clinical
spectrum is expanding mainly with the recognition of very
mild forms of peroxisomal disorders. For example, Heimler
syndrome was recently identified as a very mild form of a
peroxisomal biogenesis disorder (Ratbi et al 2015), and D-
bifunctional protein (DBP) deficiency (OMIM 261515) has
been shown to be one of the possible causes in patients with
Perrault syndrome (Pierce et al 2010). The different peroxi-
somal disorders known to date and the peroxisomal metabolic
pathways that are affected in these disorders are summarized
in Table 1, but will not be discussed in detail in this paper,
which focuses primarily on the diagnostics of peroxisomal
disorders.
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Ever since their first identification, the laboratory diagnosis
of the peroxisomal disorders has relied on biochemical mea-
surements in patient materials and, at this moment, this is still
the main diagnostic route. If a peroxisomal disorder is
suspected based on the clinical presentation, peroxisomal me-
tabolites are measured in blood and urine. When abnormal
levels of these metabolites are found, further studies are per-
formed in cultured fibroblasts, which will either exclude a
peroxisomal disorder or will provide a diagnosis.
Subsequent molecular analysis will allow identification of
the underlying mutations. Now that next generation sequenc-
ing (NGS) is becoming more readily available, an increasing
number of patients is being identified via NGS. However, also
when NGS is used in diagnostics, biochemical and functional
studies in fibroblasts often remain essential, firstly to confirm
that the correct diagnosis has been made, secondly to prove
pathogenicity of previously uncharacterized mutations and
thirdly to study the severity of the defect which is necessary
for proper clinical management of the patient. Figure 1 shows
a diagnostic flow-chart for peroxisomal disorders. In this pa-
per, a detailed review of peroxisomal diagnostics is provided,
as performed in the Laboratory Genetic Metabolic Diseases at
the Academic Medical Center in Amsterdam since the early
1980s, illustrated with examples demonstrating potential
pitfalls.
Screening for peroxisomal disorders in blood
and urine
To confirm a clinical suspicion of a peroxisomal disorder by
laboratory testing, peroxisomal metabolites should be mea-
sured in blood and urine. These metabolites include: 1) Very
long-chain fatty acids (VLCFAs) in plasma 2) C26:0 lyso PC
and C26-acylcarnitine in blood spot 3) phytanic acid and
pristanic acid in plasma, 4) THCA and DHCA in plasma
and urine (as part of bile acid analysis), 5) pipecolic acid in
plasma and 6) plasmalogens in erythrocytes.
VLCFAs are straight-chain fatty acids with a chain length of
22 carbon atoms or more. VLCFAs are endogenously synthe-
sized via chain elongation of long-chain fatty acids and accu-
mulate in case peroxisomal beta-oxidation is impaired.
VLCFAs analysis in plasma using gas-chromatography mass
spectrometry is the most widely used laboratory test for
Table 1 Peroxisomal disorders
and the affected metabolic
pathways in these disorders
Peroxisomal disorder Affected metabolic pathway
Peroxisome biogenesis disorders
Zellweger spectrum disorders (ZSDs) Phytanic acid alpha-oxidation
VLCFA and pristanic acid beta-oxidation
Plasmalogen biosynthesis
Bile acid biosynthesis
Docosahaxaenoic acid (DHA) biosynthesis
Rhizomelic chondrodysplasia punctata (RCDP) type 1 and 5 Plasmalogen biosynthesis
Phytanic acid alpha-oxidation
Peroxisomal fission disorders No obvious biochemical abnormalities
Single enzyme defects
Rhizomelic chondrodysplasia punctata (RCDP) type 2-4 Plasmalogen biosynthesis
Refsum disease Phytanic acid alpha-oxidation
Alpha-methylacyl-CoA racemase (AMACR) deficiency Pristanic acid beta-oxidation
Bile acid biosynthesis
Sterol carrier protein X (SCPx) deficiency Pristanic acid beta-oxidation
Bile acid biosynthesis
ABCD3 deficiency Bile acid biosynthesis
Acyl-CoA oxidase 1 (ACOX1) deficiency VLCFA beta-oxidation
X-linked adrenoleukodystrophy (X-ALD) VLCFA beta-oxidation
D-bifunctional protein (DBP) deficiency VLCFA beta-oxidation
Pristanic acid beta-oxidation
Bile acid biosynthesis
Docosahaxaenoic acid (DHA) biosynthesis
Bile acid-CoA:amino acid N-acyltransferase (BAAT) deficiency Bile acid conjugation
Primary hyperoxaluria Glyoxylate detoxification
Acatalasemia Hydrogen peroxide detoxification
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peroxisomal disorders (Vreken et al 1998). In this test, all
lipids are hydrolyzed during sample work-up so that total
levels of C26:0, C24:0 and C22:0 are measured. This allows
calculation of the C26/C22 ratio, which is increased in ZSD,
X-ALD (OMIM 300100), ACOX1 (OMIM 264470) and
DBP deficiency. Recently, C26:0 lyso PC measurement in
blood spot using liquid chromatography tandem mass spec-
trometry (LC-MS/MS) has been introduced as a screening
parameter (Theda et al 2014) but this is operational in a limited
number of laboratories only. C26:0 lyso PC is a marker for
C26:0 accumulation in the phospholipid fraction. The sample
work-up is simple and the method is already used for newborn
screening for X-ALD in the state of New York and will be
introduced in other countries in the near future. As another
biomarker for VLCFA accumulation, C26-carnitine can be
measured in blood spot using LC-MS/MS (Rizzo et al 2003).
It is important to mention that VLCFAs may be abnormal
in the absence of peroxisomal dysfunctions. For example, ex-
cess dietary intake via peanut consumption (Lam et al 2012)
or a ketogenic diet (Theda et al 1993) can lead to increased
levels of plasma VLCFAs, which is a diagnostic pitfall.
Phytanic and pristanic acid measurement can be incorpo-
rated in the VLCFA analysis when an alkaline hydrolysis step
is included in the work up of the sample (Vreken et al 1998).
The branched-chain fatty acids phytanic and pristanic acid
cannot be endogenously synthesized and are exclusively de-
rived via the diet either as phytanic and pristanic acid itself or
through their precursor phytol (Wanders et al 2011). Phytol is
part of the chlorophyll molecule and can be released by bac-
teria in the gut of ruminants. Depending on the age and the
diet of the patient, the branched-chain fatty acids are increased
in Refsum disease (OMIM 266500), RCDP type 1 and 5,
ZSDs, DBP, alpha-methylacyl-CoA racemase (AMACR,
OMIM 614307), sterol carrier protein X (SCPx, OMIM
613724) and possibly ATP-binding cassette sub-family D
member 3 (ABCD3) deficiency. In Refsum disease and
RCDP type 1 and 5, the major accumulating metabolite is
phytanic acid due to a defect of alpha-oxidation, whereas in
DBP, AMACR and SCPx deficiency the pristanic/phytanic
acid ratio is increased because peroxisomal beta-oxidation of
pristanic acid is impaired and phytanic acid accumulation is
only secondary. The only patient with ABCD3 deficiency
identified so far did not show accumulation of phytanic or
pristanic acid but studies in the mouse model did point to a
role for ABCD3 in the transport of branched-chain fatty acids
into the peroxisome (Ferdinandusse et al 2015). Other, longer
surviving ABCD3 patients could therefore possibly be identi-
fied with accumulation of the branched-chain fatty acids.
Bile acid analysis by electrospray ionization-tandem mass
spectrometry (ESI-MS/MS) in plasma and urine provides in-
formation about the primary C24-bile acids cholic acid and
chenodeoxycholic acid but also about the peroxisomal C27-
bile acid intermediates di- and trihydroxycholestanoic acid (D/
THCA) and the C29-dicarboxylic acid (Bootsma et al 1999).
Bile acids are formed in the liver from cholesterol and, in the
major pathway for bile acid biosynthesis, peroxisomal short-
ening of the side-chain by one cycle of beta-oxidation is re-
quired (Ferdinandusse and Houten 2006). C27-bile acids can
be detected in plasma and urine from patients with a ZSD as
well as in DBP, AMACR, SCPx and ABCD3 deficiency
(Ferdinandusse and Houten 2006; Ferdinandusse et al 2009,
2015; Clayton 2011). C29-dicarboxylic acid, which is formed
via chain-elongation of THC-CoA, is only found in plasma
because it is poorly excreted in urine. Characteristic for
AMACR deficiency is the exclusive accumulation of (25R)-
DHCA and (25R)-THCA since they require racemization by
AMACR before peroxisomal beta-oxidation of the side-chain
can occur. In DBP deficiency, another important accumulating
C27-bile acid intermediate is 24-OH-THCA. In SCPx defi-
ciency, only trace amounts of DHCA and THCA are present
but urine bile acid analysis reveals a characteristic excretion of
bile alcohol glucuronides (m/z 611, 613, 627, 629, 643 and
645). In urine, hydroxylated forms of THCA are present since
hydroxylation increases polarity and thereby urinary
Clinical symptoms indicative of peroxisomal disorder
Next Generation SequencingBiochemical studies in
blood, urine and fibroblasts
Abnormal Normal Known mutation • Variant of unknown
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Fig. 1 Diagnostic flow-chart for peroxisomal disorders
excretion. The presence of the taurine conjugate of hydroxyl-
ated 24-ene-THCA (m/z 570) and dihydroxylated 24-ene-
THCA (m/z 586) is characteristic for patients with DBP
deficiency.
Both in ZSDs and DBP deficiency it has been shown that
the extent of the peroxisome/DBP deficiency corresponds to
the extent of the deficiency of bile acid biosynthesis (Gootjes
et al 2002; Ferdinandusse et al 2006a, b; Berendse et al 2015).
Patients with a milder clinical presentation and longer survival
tend to accumulate less DHCA and THCA. C27-bile acids can
even be completely normal; in a large cohort of DBP-deficient
patients it was shown that in 26 % of the patients no C27-bile
acids were present in plasma (Ferdinandusse et al 2006a, b).
Pipecolic acid analysis by ESI-MS/MS in plasma (or urine)
is a useful parameter in the diagnosis and classification of
peroxisomal disorders (Peduto et al 2004). Since L-pipecolic
acid oxidase, involved in the breakdown of pipecolic acid, is a
peroxisomal enzyme, pipecolic acid accumulates in ZSDs but
not in peroxisomal single enzyme defects.
Measurement of plasmalogens by gas chromatography
(GC) in erythrocytes should be included in the screening for
peroxisomal disorders to investigate a possible defect in
plasmalogen biosynthesis (Dacremont and Vincent 1995).
Plasmalogens are etherphospholipids and the first two steps
of the plasmalogen biosynthesis pathway are peroxisomal
(Brites et al 2004; Braverman and Moser 2012). The main
biochemical defect in all types of RCDP is a deficiency of
plasmalogens but also in the ZSDs, there is a plasmalogen
deficiency. The phenotype of patients within the RCDP spec-
trum correlates well with plasmalogen levels, with the lowest
levels of plasmalogens in erythrocytes in patients with the
severe phenotype (Braverman et al 2002; Bams-Mengerink
et al 2013). In ZSDs, plasmalogen levels are low in severely
affected patients and can be completely normal in milder
patients.
Peroxisomal studies in cultured skin fibroblasts
Studies of peroxisomes and peroxisomal functions in cultured
primary skin fibroblasts are important and even can be essen-
tial in the diagnostic process for peroxisomal disorders.
Several tests are available to study different aspects of perox-
isomes and their functions (see Table 2).
First, as in blood, specific peroxisomal metabolites can be
measured in cultured skin fibroblasts. These include VLCFAs,
C26:0 lyso PC and plasmalogens (Dacremont et al 1995;
Dacremont and Vincent 1995). VLCFAs and C26:0 lyso PC
are abnormal in ZSDs, X-ALD, ACOX1 and DBP deficiency,
and plasmalogens are deficient in ZSDs and RCDP.
Second, immunofluorescence microscopy analyses can be
performed with antibodies specific for peroxisomal matrix or
membrane proteins to study the presence/absence of import-
competent peroxisomes and peroxisomal membranes
(Wanders et al 1989) (Fig. 2). Catalase immunofluorescence
microscopy analysis has proven to be the most sensitive test in
fibroblasts for the diagnosis of ZSDs. In mild patients, all
biochemical testing in blood and fibroblasts can even be nor-
mal, with only an aberrant peroxisomal staining upon immu-
nofluorescence microscopy analysis. In severe patients,
import-competent peroxisomes are absent in all cells, but the
cells may still contain peroxisomal membrane remnants
(ghosts). These ghosts are enlarged when compared to the size
of functional peroxisomes. Whether ghosts are still present
depends on the function of the defective PEX gene but also
on the severity of the mutations. In milder patients often a
mosaic pattern is observed with cells without peroxisomal
staining, cells with a reduced number of peroxisomes and cells
with a normal peroxisomal staining. The mosaic pattern varies
for all patients, for example the mosaic can exist mainly of
cells lacking peroxisomes but also mainly of cells with func-
tional peroxisomes, and the observed pattern also depends on
culture conditions. When fibroblasts with a peroxisomal mo-
saic pattern are cultured at 40 °C, the peroxisome biogenesis
defect is often exacerbated resulting in the loss of import-
competent peroxisomes (Gootjes et al 2004). Peroxisomes
can also be enlarged in ZSDs, although this has only been
observed in a minority of patient cells (e.g. PEX16
(Ebberink et al 2010) and PEX11β defects (Ebberink et al
2012; Thoms and Gartner 2012)). Most often, however, en-
larged peroxisomes point to a peroxisomal fatty acid oxidation
defect. Fibroblasts of ACOX1-deficient patients show a mark-
edly reduced number of very enlarged peroxisomes
(Ferdinandusse et al 2007). This phenotype, although less
Table 2 Functional tests available for peroxisomal diagnostics in
cultured skin fibroblasts
Metabolite measurement
Very long-chain fatty acid analysis







Acyl-CoA oxidase 1 (ACOX1)
D-bifunctional protein (DBP)
Sterol carrier protein X (SCPx)
Pathway analyses
Phytanic acid alpha-oxidation activity with [1-14C] phytanic acid
Pristanic acid beta-oxidation activity with [1-14C] pristanic acid
C26:0 beta-oxidation with [1-14C] C26:0
D3-C22 loading test (VLCFA metabolism)
534 J Inherit Metab Dis (2016) 39:531–543
pronounced, can also be observed in fibroblasts of DBP-
deficient patients, but not in all cases especially not in fibro-
blasts of milder patients (Ferdinandusse et al 2006a, b).
Fibroblasts of other peroxisomal fatty acid oxidation disorders
(i.e. X-ALD, Refsum disease, AMACR and SCPx deficiency)
have a normal number of morphologically normal peroxi-
somes. Next to providing information about the localization
of peroxisomal proteins, immunofluorescence microscopy
analysis is also useful to study the presence or absence of
the peroxisomal proteins for whichmutations have been found
in the encoding genes. For example, it has been reported that
77 % of all non-recurrent ABCD1 mutations result in the ab-
sence of adrenoleukodystrophy protein (ALDP) (http://www.
x-ald.nl) (Kemp et al 2012). In fibroblasts of female ABCD1
carriers, a mosaic pattern can be observed due to X-
chromosome inactivation (Kemp et al 2012). In patients with
CCADS (contiguous ABCD1 DXS1357E (BAP31) deletion
syndrome, OMIM 300475) there is also no expression of
ALDP (Corzo et al 2002). The only ABCD3-deficient patient
was initially diagnosed by the serendipitous finding of ab-
sence of ABCD3 staining upon routine immunofluorescence
microscopy analysis when screening for peroxisomal disor-
ders in fibroblasts was performed (Ferdinandusse et al 2015).
Third, the flux through the peroxisomal fatty acid alpha-
and beta-oxidation systems can be determined with
radiolabelled substrates (i.e. [1-14C]-phytanic acid, [1-14C]-
pristanic acid, [1-14C]-C26:0) (Wanders and Van Roermund
1993; Wanders et al 1995b). With these methods the end-
products of fatty acid oxidation are measured (i.e. [14C]CO2
and [14C]-labelled acid soluble products such as acetate, pro-
pionate and Krebs cycle intermediates). Measurement of fatty
acid oxidation activities with different substrates allows dif-
ferentiation between different peroxisomal disorders and
therefore provides an effective tool to establish the diagnosis
in a patient. In addition, it provides information about the
severity of the defect. A correlation between the severity of
the clinical presentation and the residual peroxisomal fatty
acid oxidation activity has been shown for ZSDs and DBP
Fig. 2 Microscopical analyses of cultured skin fibroblasts.
Immunofluorescence microscopy analyses using a specific antiserum
against catalase, a peroxisomal matrix enzyme, reveals a typical
punctuated staining in fibroblasts of a control subject (a and d). In
severe Zellweger spectrum disorders (ZSD) there is no peroxisomal stain-
ing (b), but in milder ZSD patients a mosaic pattern can be observed
composed of cells with a normal peroxisomal staining, cells with a re-
duced number of peroxisomes and cells with no peroxisomal staining (c).
Typically, fibroblasts of patients with D-bifunctional protein (DBP) defi-
ciency (e) or acyl-CoA oxidase 1 (ACOX1) deficiency show a reduced
number of enlarged peroxisomes. PEX11β deficiency results in elongat-
ed and enlarged peroxisomes (f). Fibroblasts from DLP1/DRP1 patients
(h and i) have fewer peroxisomes (red dye) which are often arranged like
beads on a string, and the mitochondria are elongated and interconnected
(green dye, TOM20 antibody)
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deficiency (Gootjes et al 2002; Ferdinandusse et al 2006b).
Phytanic acid oxidation activity is deficient in fibroblasts of
patients with Refsum disease, RCDP type 1 and 5 and ZSDs,
but can also be reduced in fibroblasts of DBP-deficient pa-
tients most likely due to the reduced number of functional
peroxisomes in severe patients. Pristanic acid beta-oxidation
activity is deficient in ZSDs and DBP deficiency and only
partly deficient in AMACR, SCPx and ABCD3 deficiency.
C26:0 beta-oxidation activity is deficient in ZSDs, X-ALD,
ACOX1 and DBP deficiency. In addition to these tests with
radiolabelled substrates, peroxisomal fatty acid oxidation of
straight-chain fatty acids can be studied by loading fibroblasts
for 3 days with deuterated (D3) C22:0 followed by fatty acid
analysis with tandem mass spectrometry (Kemp et al 2004;
Ebberink et al 2012). Labelled and unlabelled fatty acids with
chain lengths ranging from 16 carbon atoms up to 30 carbon
atoms are measured. Although this test does not provide in-
formation about the flux through the beta-oxidation system,
since the end products of beta-oxidation are not measured, the
test provides information about VLCFA metabolism and al-
lows detection of peroxisomal disorders with a defect in per-
oxisomal beta-oxidation of VLCFAs (ZSD, X-ALD, ACOX1
and DBP deficiency). Not only a reduced production of D3-
C16:0 is observed in these disorders as reflected in a reduced
D3-C16/D3-C22 ratio, but also an increased production of
D3-C26:0 levels via chain elongation (see Fig. 3).
Fourth, enzyme activity measurements can be performed
to determine the activity of single enzymes. These include
activity measurement of dihydroxyacetonephosphate acyl-
transferase (DHAPAT), ACOX1, DBP and SCPx. DHAPAT
activity is deficient in RCDP type 2 (OMIM 222765) caused
by mutations in the encoding geneGNPAT, but is also reduced
in all other types of RCDP, except RCDP type 4 (FAR1 defi-
ciency), and in ZSDs (Brites et al 2004; Braverman andMoser
2012). This is caused by impaired import of DHAPAT into the
peroxisome and/or impaired import of alkyl-DHAP-synthase
(AGPS) in combination with the fact that DHAPAT is only
stable and can only function optimally when it forms an intra-
peroxisomal complex with functional AGPS (de Vet et al
1999; Itzkovitz et al 2012). It should be noted that in attenu-
ated forms of RCDP type 1 and 5, and in RCDP type 3
(OMIM 600121) with normal, but non- functional, protein
levels of AGPS, DHAPAT activity can be (near) normal.
ACOX1 activity can be measured in fibroblast homoge-
nates with C16-CoA as substrate in the presence of FAD,
followed by separation and detection of the products C16:1-
CoA and 3-OH-C16-CoA using (ultra-)high pressure liquid
chromatography ((U)HPLC) on a reversed-phase column.
ACOX1 activity is deficient in patients with mutations in the
encoding gene (Ferdinandusse et al 2007). To some extent
there is a correlation between clinical severity and residual
activity, but it should be noted that the other peroxisomal
oxidase (ACOX2, branched-chain specific) also displays
some activity towards C16-CoA as substrate (Vanhove et al
1993), hampering an accurate determination of residual
ACOX1 activity. ACOX1 activity is normal in fibroblasts of
ZSD patients because activity measurement is performed in a
cell homogenate and ACOX1 is stable in the cytosol, at least
in fibroblasts. ACOX1 activity is increased in DBP deficiency
due to upregulation of its expression (Ferdinandusse et al
2003).
DBP and SCPx can be measured in a single assay using
THC:1-CoA as substrate, followed by separation and detec-
tion of the products using (U)HPLC on a reversed-phase col-
umn (van Grunsven et al 1999; Ferdinandusse et al 2006a, b).
In this assay, the substrate for the SCPx reaction is formed by
endogenous DBP activity, which could in theory be a problem
when SCPx diagnostics is requested in a DBP-deficient pa-
tient. In practice, however, this will not occur since clinically



























A BFig. 3 Loading test with D3-
C22:0 in cultured skin fibroblasts.
Fibroblasts of control subjects
and patients with X-linked adre-
noleukodystrophy (X-ALD), a
Zellweger spectrum disorder
(ZSD) and D-bifunctional protein
deficiency (DBP) were incubated
for 3 days with 30 μM D3-C22:0
followed by fatty acid analysis
using tandem mass spectrometry.
In the patient cell lines, break-
down of D3-C22:0 is reduced as
reflected by a reduced D3-C16:0/
D3-C22:0 ratio (a) and chain
elongation is increased as
reflected by an increased D3-
C26:0 formation (b). Whiskers
indicate mean± standard
deviation
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DBP-deficient patients, DBP activity is markedly reduced.
Remarkably, this is also the case in mild patients with normal
peroxisomal parameters in blood and without VLCFA accu-
mulation in fibroblasts (Ferdinandusse et al 2006a; McMillan
et al 2012; Lines et al 2014). DBP activity measurement can
also be performed in lymphocytes, allowing rapid screening
for DBP deficiency in blood. DBP activity in fibroblast ho-
mogenates from ZSD patients is somewhat reduced but not
fully deficient, indicating that DBP can be active in the
cytosol.
Fifth, immunoblot analysis can be performed to study the
expression of peroxisomal proteins but also the processing of
peroxisomal proteins (Wanders et al 1995a). Several peroxi-
somal proteins are processed inside the peroxisomes by a pro-
tease and thus the immunoblot profiles of these proteins
provide information about the presence of import-competent
peroxisomes in fibroblasts of a patient and the severity of the
potential peroxisome biogenesis defect. ACOX1 and peroxi-
somal 3-ketoacyl-CoA thiolase immunoblotting are often per-
formed in peroxisomal diagnostics for this purpose (Fig. 4).
Especially processing of 3-ketoacyl-CoA thiolase provides
valuable information not only about ZSDs but also allows
distinction between the different types of RCDP. Processing
of 3-ketoacyl-CoA thiolase does not occur in RCDP type 1
and the recently reported type 5. In mild ZSDs, both the un-
processed and processed form of peroxisomal 3-ketoacyl-
CoA thiolase can be observed (see Fig. 4).
Immunoblot analysis is an important test in biochemical
prenatal testing for ZSDs in chorionic villous biopsy material
but also for DBP deficiency as an additional test next to en-
zyme activity measurement in case the index patient has prov-
en to have no DBP protein expression (Fig. 4).
Sixth, complementation studies can be performed in fibro-
blasts without import-competent peroxisomes to determine
which PEX gene is defective in the patient’s cells and subse-
quently allowing direct sequencing of this gene. To this end, a
PEX cDNA transfection assay has been developed in which
the different pcDNA3-PEX expression vectors are co-
transfected separately but together with eGFP-SKL into pa-
tient fibroblasts (Ebberink et al 2011). If the correct PEX
cDNA is transfected complementation occurs and restoration
of peroxisome biogenesis can be observed by fluorescence
microscopy. This assay can also be performed at 40 °C for
cell lines which display different degrees of peroxisomal mo-
saicism that are sensitive to culturing at 40 °C, which exacer-
bates the defect in peroxisome biogenesis. In addition, this
complementation assay can be used to show that defects iden-
tified by NGS are responsible for the phenotype observed in
patient cells. For example, genetic complementation was used
to demonstrate that variants in the PEX1 and PEX6 genes
identified with whole exome sequencing are the cause of the
aberrant peroxisomal phenotype in fibroblasts of Heimler syn-
drome patients (Ratbi et al 2015).
The importance of functional studies in fibroblasts
for peroxisomal diagnostics
Since the discovery in 1973 that Zellweger syndrome is
caused by the absence of functional peroxisomes
(Goldfischer et al 1973), studies have been performed in fi-
broblasts of peroxisomal patients to investigate the role of
peroxisomes in metabolism. These studies have led to more
insight in the different functions of peroxisomes and the met-
abolic pathways localized partly or fully in peroxisomes, and
to the development of many different tests which can be used
for peroxisomal diagnostics.When diagnostics for peroxisom-


















Fig. 4 Immunoblot analysis in fibroblast homogenates. Immunoblot
analysis with antibodies against peroxisomal 3-ketoacyl-CoA thiolase
reveals the mature processed form of 41 kDa in control fibroblasts (C),
but the unprocessed form of 44 kDa in fibroblasts of a patient with a
Zellweger spectrum disorder (ZSD). In mild ZSDs both forms can be
present. Immunoblot analysis with antibodies against acyl-CoA oxidase
1 (ACOX1) reveals the full length protein of 70 kDa and the processed
forms of 50 and 20 kDa in control fibroblasts, but in ZSD fibroblasts only
the 70 kDa is observed. Immunoblot analysis with antibodies against D-
bifunctional protein (DBP) reveals the absence of protein in a DBP-
deficient patient
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metabolite abnormalities in blood, follow-up studies in fibro-
blasts are essential to establish the correct diagnosis. Also
when NGS techniques are used, functional studies in fibro-
blasts remain an important part of the diagnostic process.
Below, the value of fibroblast studies in peroxisomal diagnos-
tics will be illustrated with different examples.
Based on the clinical presentation and metabolite abnor-
malities in blood solely, it can be hard or even impossible to
distinguish between different peroxisomal disorders.
At the severe end of the clinical spectrum, in the neonatal-
infantile and childhood period, the clinical presentation of
DBP and ACOX1 deficiency can be indistinguishable from
ZSDs, with severe hypotonia, seizures, liver disease and
dysmorphia (Ferdinandusse et al 2006a, 2007; Poll-The and
Gartner 2012). Also MRI-features in DBP deficiency resem-
ble those of ZSDs (van der Knaap et al 2012). VLCFAs are
abnormal in all of these disorders and in the infantile period,
dietary-dependent phytanic acid and pristanic acid levels are
not yet elevated in ZSDs and DBP deficiency and thus cannot
be used for discrimination between the different disorders.
Bile acid and plasmalogen analysis would allow differentia-
tion between these defects in severely affected patients, but
this is only performed in a limited number of laboratories. In
these cases, fibroblast studies should be performed to establish
the diagnosis in the patient (see Table 3 for comparison of
fibroblasts studies in a classical ZSD and a DBP patient).
At the mild end of the clinical spectrum, in the adolescent
or young adult period, the distinction between mild ZSDs and
AMACR or SCPx deficiency can be difficult to make in pa-
tients with cerebellar ataxia, peripheral neuropathy and reti-
nopathy. Because VLCFA levels in mild ZSDs can be normal
or even normalize with age (Berendse et al 2015), increased
pristanic acid levels can be the only clear abnormality in plas-
ma. In combination with the clinical presentation, a ZSD is
unjustly not considered in these patients until fibroblast stud-
ies show a mild peroxisome biogenesis defect. For example,
spastic paraplegia and mild deafness in a female patient at age
33 years in combination with repeated increased pristanic acid
levels in plasma raised the suspicion of AMACR deficiency.
Analysis of the AMACR gene, however, did not reveal path-
ogenic mutations. Fibroblasts were sent in for SCPx enzyme
analysis. SCPx activity was within the reference range, but
further peroxisomal screening revealed a mild ZSD caused
by bi-allelic mutations in PEX6 (see Table 3, patient 3). In
addition, a patient with an acute neurodegenerative disease
course and with abnormal VLCFAS all highly suggestive of
X-ALD, was diagnosed as a late onset ZSD after peroxisomal
studies in fibroblasts (Tran et al 2014).
Fibroblasts studies can also differentiate between the dif-
ferent types of RCDP, which are clinically indistinguishable
especially at the severe end of the spectrum and which all have
a plasmalogen deficiency in common (Wanders and
Waterham 2006a, b; Braverman and Moser 2012; Buchert
et al 2014; Baroy et al 2015). In addition, it can classify pa-
tients with a Refsum-like phenotype and increased phytanic
acid levels in the RCDP spectrum (van den Brink et al 2003)
and show that the patient does not suffer from classical
Refsum disease but an attenuated form of RCDP type 1 (see
Table 3, patient 6). For example, repeatedly very high
phytanic acid levels (over 700 μM) were found in plasma of
a 9 year old girl with neurological symptoms, suggesting clas-
sical Refsum disease. Fibroblast studies did not only reveal a
deficient phytanic acid alpha-oxidation, but also a reduced
DHAPAT activity and the presence of unprocessed 3-
ketoacyl-CoA thiolase on Western blot. Combined these re-
sults pointed to a PEX7 defect, which was confirmed by mo-
lecular analysis.
Peroxisomal functions in fibroblasts can be abnormal in
peroxisomal patients with normal peroxisomal metabolites in
blood. Several patients with DBP or ACOX1 deficiency or a
ZSD have been reported with normal peroxisomal parameters
in blood in whom diagnosis was only established or confirmed
by studies in fibroblasts (Soorani-Lunsing et al 2005;
Rosewich et al 2006; McMillan et al 2012; Lines et al 2014;
Ratbi et al 2015). Especially in milder DBP patients the only
identifiable defect in blood and fibroblasts can be DBP activ-
ity and expression (see Table 3, patient 5), which is a well-
recognized diagnostic pitfall for this disorder. At the very mild
end of the ZSD spectrum, in patients presenting with Heimler
syndrome, the only identified abnormality in the extensive
peroxisomal screening in blood and fibroblasts performed,
was the aberrant peroxisomal staining with immunofluores-
cence microscopy analysis, which exacerbated after culturing
the fibroblasts at 40 °C. This means that when the clinical
symptoms of a patient are suggestive of a peroxisomal disor-
der but peroxisomal metabolites in blood and urine are nor-
mal, studies in fibroblasts are still warranted. It must be noted
that a ZSD with metabolite abnormalities in blood but normal
peroxisomal functions in fibroblasts is also possible. For ex-
ample, a patient with a defect in PEX10 showed normal pres-
ence of functional peroxisomes in fibroblasts (Steinberg et al
2009). Hence, a peroxisomal disorder cannot be fully exclud-
ed based on normal peroxisomal studies in fibroblasts alone.
The recently identified disorders of peroxisomal fission can
be demonstrated only by microscopy in fibroblasts, since per-
oxisomal parameters in blood and cells are mostly normal in
these disorders. Immunofluorescence microscopy analysis in
fibroblasts of patients with a defect of PEX11β, DLP/DRP1
and MFF show a clearly aberrant peroxisomal staining char-
acteristic for the underlying defect (Fig. 2). Fibroblasts with a
defect of PEX11β, involved in elongation, show enlarged and
elongated peroxisomes at 37 °C, while at 40 °C catalase stain-
ing becomes cytosolic (Ebberink et al 2012). Fibroblasts with
a defect of DLP/DRP1 and MFF (Waterham et al 2007;
Shamseldin et al 2012), involved in fission of peroxisomes,
show strings of peroxisomes.
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When no mutations are identified by genetic analysis, fi-
broblast studies can still provide the diagnosis, also allowing
biochemical prenatal analysis based on these results. For ex-
ample, in a boy with severe hypotonia, seizures,
polymicrogyria, blindness and dysmorphia, DBP deficiency
was suspected based on the abnormal VLCFA and bile acid
profiles. DHAPAT activity was analysed and found normal.
Subsequently, DNA was sent for mutation analysis of the
HSD17B4 gene but no mutations were identified. Further fi-
broblast studies were recommended and confirmed unambig-
uously DBP deficiency in the patient (see Table 3, patient 4).
In case NGS is chosen as the diagnostic approach before
biochemical studies are performed, biochemical and function-
al studies often remain essential. First, it is very important to
confirm that the right diagnosis has been made for proper
clinical management of the patient. Second, if they do not
involve loss-of-function mutations and have not been func-
tionally characterized previously, pathogenicity of the identi-
fied DNAvariants has to be proven before genetic counseling
can be provided to these families. Obviously, this is also im-
perative before prenatal diagnosis can be offered. If variants
are reported as pathogenic without functional studies to actu-
ally prove pathogenicity, it may be detrimental in the diagnos-
tic process of other patients and genetic counselling in their
families. For example, whole exome sequencing identified a
homozygous c.315A>C variant in PEX1 in two siblings from
consanguineous parents with intellectual disability and dys-
morphic features. VLCFA and phytanic acid levels were re-
ported to be normal. Fibroblasts studies revealed no abnormal-
ities in any of the peroxisomal parameters, providing no evi-
dence of a peroxisome biogenesis defect as the underlying
cause of the clinical symptoms. On the other hand, it is also
important to perform complete studies in fibroblasts to prevent
the possibility that a diagnosis with pathogenic mutations is
unjustly discarded. For example, a homozygous mutation in
PEX13was recently identified by whole exome sequencing in
a boy with normal psychomotor development, who presented
at the age of 5 years with ataxia, dysarthria and learning dis-
ability. MRI showed hypomyelinations associated with cere-
bral and vermian atrophy. Fibroblasts studies were performed
but revealed completely normal DHAPAT activity, VLCFAs,
C26:0 lyso PC and immunoblot profiles for ACOX1 and 3-
ketoacy-CoA thiolase (Table 3, patient 2). However, catalase
immunofluorescence microscopy analysis revealed a mosaic
pattern composed of cells with a normal peroxisomal staining,
cells with a reduced number of peroxisomes and cells without
import-competent peroxisomes showing that the patient in-
deed suffered from a ZSD. At 40 °C all catalase staining
became cytosolic allowing complementation studies at this
temperature and confirmation of the PEX13 defect
(Submitted for publication). Third, DNA variants, which are
unlikely to be pathogenic according to prediction programs,
can still be disease-causing, which can be demonstrated by
biochemical and functional studies. Based on molecular anal-
ysis alone these patients may remain without diagnosis and
therefore without treatment. For example, in a 5-year old boy
presenting with hypotonia and abnormal pain sense in the
legs, secondary enuresis and normal cognition, X-ALD was
suspected after VLCFA analysis in blood was abnormal. This
suspicion initially seemed not confirmed by mutation analysis
of ABCD1, which revealed a hemizygous c.1-22C>T variant
that had not been reported previously but was not predicted as
pathogenic. Fibroblast studies, however, showed unambigu-
ously that the patient suffered from X-ALD since ALDP ex-
pression was absent in most but not all cells and VLCFAs
were abnormal in repeated analyses (see Table 3, patient 7).
Fourth, functional studies can provide information about the
severity of the defect and can therefore have prognostic value
for patients, their parents and their physicians. Fifth, if muta-
tions in novel peroxisomal genes are identified, the defect has
to be characterized by biochemical studies in blood and func-
tional studies in fibroblasts.
When (one of) the causative mutations cannot be detected
by DNA analysis in patients with a ZSD, DBP or ACOX1
deficiency, biochemical prenatal testing is possible, but only
after biochemical characterization in fibroblasts of the index
patient. In chorionic villous biopsy material, measurement of
DBP and ACOX1 activity is possible and in case of a ZSD,
DHAPAT activity is measured and immunoblot analysis of
ACOX1 and 3-ketoacyl-CoA thiolase performed. In addition,
VLCFA analysis and immunofluorescence microscopy anal-
ysis is performed in cultured chorionic villous cells. These last
two tests can also be performed in cultured amniocytes but
this is not preferred because the interpretation is more difficult
and only two tests can be performed as opposed to four dif-
ferent tests in chorionic villous material.
Concluding remarks
Much of our knowledge on peroxisomal functions and
the consequences of peroxisomal dysfunction is based
on biochemical investigations in tissues, body fluids
and fibroblasts of patients with peroxisomal disorders.
Biochemical studies followed by functional studies in
fibroblasts are crucial in the traditional diagnostic
work-up for these disorders, which mostly starts with
a clinical suspicion of a peroxisomal disorder. Also
when NGS techniques are used, biochemical and func-
tional studies often remain necessary to confirm the di-
a g no s i s , p r o v e p a t h og en i c i t y o f p r e v i ou s l y
uncharacterized mutations and to characterize the sever-
ity of the defect. Thus, biochemical and functional stud-
ies are imperative for proper clinical management of the
patients and genetic counseling in the family.
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